Overview

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Status:
Not yet recruiting

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

An open, non-randomized Phase I trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory pediatric neuroblastoma or solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Ascentage Pharma Group Inc.

Collaborator:

Suzhou Yasheng Pharmaceutical Co., Ltd.